A Sponsor’s Guide to Navigating the EU Joint Clinical Assessment Framework
Prioritising Patient-Driven Outcomes for Rare Disease Biotechs The Joint Clinical Assessment (JCA) framework, established under the EU Health Technology[…]
The Challenge of HTA: Supporting Patient Advocacy Groups Effectively
The intersection of rare diseases with Health Technology Assessment (HTA) is a complex juncture in the modern[…]